JAY CHANMUGAM: Open Payments
NPI 1518905207 · ORANGE CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,656 in 69 payments from 13 companies in 2025. Trend: 2023 $1,897 · 2024 $2,086 · 2025 $2,656
Food & beverage: $2,656
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $701 |
| ABBVIE INC. | 17 | $634 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $354 |
| Novo Nordisk Inc | 9 | $331 |
| Eisai Inc. | 4 | $275 |
| GlaxoSmithKline, LLC. | 5 | $121 |
| Exact Sciences Corporation | 4 | $86 |
| PFIZER INC. | 3 | $55 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Indivior Inc. | 1 | $21 |
Products named: VRAYLAR, CAPLYTA, AIRSUPRA, BREZTRI, Ozempic, Leqembi, QULIPTA, TRELEGY ELLIPTA.
Industry payments across FL — which companies pay providers there.
